153 related articles for article (PubMed ID: 30348718)
1. Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma.
Zablockis R; Žurauskas E; Danila E; Gruslys V
In Vivo; 2018; 32(6):1571-1579. PubMed ID: 30348718
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.
Lin CS; Liu TC; Lai JC; Yang SF; Tsao TC
Int J Med Sci; 2017; 14(13):1410-1417. PubMed ID: 29200955
[TBL] [Abstract][Full Text] [Related]
4. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
[TBL] [Abstract][Full Text] [Related]
6. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
[TBL] [Abstract][Full Text] [Related]
7. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Study of Surgical Treated Lung Adenocarcinoma with Ground Glass Nodule Component.
Xu Y; Zheng M; Wang N; Wang R
Med Sci Monit; 2019 Nov; 25():8492-8498. PubMed ID: 31710020
[TBL] [Abstract][Full Text] [Related]
10. Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
Kim IA; Lee JS; Kim HJ; Kim WS; Lee KY
BMC Cancer; 2018 Jul; 18(1):768. PubMed ID: 30055587
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
Ke SB; Qiu H; Chen JM; Shi W; Chen YS
Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
[TBL] [Abstract][Full Text] [Related]
12. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
13. Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma.
Wang JL; Fang CL; Tzeng YT; Hsu HL; Lin SE; Yu MC; Bai KJ; Wang LS; Liu HE
J Biomed Sci; 2018 Jun; 25(1):53. PubMed ID: 29950164
[TBL] [Abstract][Full Text] [Related]
14. [Trend analysis and clinicopathological characteristics of 198 young patients with advanced lung adenocarcinoma].
Li YF; Wang Y; Li JL; Hao XZ; Hu XS; Wang HY
Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):750-755. PubMed ID: 27784458
[No Abstract] [Full Text] [Related]
15. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
16. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Chang S; Hur J; Hong YJ; Lee HJ; Kim YJ; Han K; Choi BW
AJR Am J Roentgenol; 2018 Jan; 210(1):43-51. PubMed ID: 29091002
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
18. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
20. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.
Tseng JS; Yang TY; Tsai CR; Chen KC; Hsu KH; Tsai MH; Yu SL; Su KY; Chen JJ; Chang GC
J Thorac Oncol; 2015 Apr; 10(4):603-10. PubMed ID: 25514801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
